Read Why Shares Of Nano Cap Cumberland Pharma More Than Doubled

The FDA has approved expanded labeling for Cumberland Pharmaceuticals Inc's CPIX Caldolor, an intravenously delivered formulation of ibuprofen, to now include use in pre-operative administration.
The non-narcotic pain reliever can now be administered just before surgery to enable patients to wake up from their procedure in significantly less pain.
Supporting this expanded use of Caldolor, a study of orthopedic surgical pain confirmed the significant pain reduction when the product was administered every six hours (started pre-operatively) with supplemental morphine available on an as-needed basis.
A total of 185 patients were randomized and treated with either Caldolor 800 mg or placebo and morphine.
Efficacy was demonstrated as a statistically significant greater reduction in pain intensity over 24 hours postoperatively for patients treated with Caldolor than those receiving placebo.
Caldolor is indicated for pain management and fever reduction.
It was the first FDA-approved intravenous therapy for fever.
See here Benzinga's Full FDA Calendar.
Price Action: CPIX shares are up 111.4% at $4.65 during the premarket session on the last check Tuesday.

Momentum-

Growth24.18

Quality-

Value41.99

Short

Medium

Long